Elliot Bland Email & Phone Number

Buckhurst Hill, GB

GB

London, Greater London, GB

London, GB

• QMI Ltd provides innovation management and commercialisation services to Queen Mary University of London and Barts Health Trust.
• Generated over 50% of company licence income 2013-2014, 2014-2015 and 2015-2016.
• Identification, analysis and evaluation (scientific, IP, commercial) of novel technologies.
• Business development: targeting and connecting with potential partners for out-licensing and collaboration activities, financial modelling, negotiating to conclusion various agreements (e.g. licensing, collaboration).
• Put together non-clinical package for submission to MHRA, negotiated supply of API and finished product to enable Phase IIa study in trauma.
• Developed nonclinical safety plans for various programmes, submitted to and agreed by MHRA.

Watford, UK, GB

• SLA Pharma is a speciality pharmaceutical company focusing on gastrointestinal diseases with unmet needs and orphan diseases.
• Out-licensed phase III development to pan-European company.
• Generated significant company income through licensing activities.
• Updated in-house financial modelling process to evaluate market potential and deal terms.
• Leading on all business development activities including: targeting and building relationships with potential partners, preparing term sheets and negotiating licensing agreements to conclusion.
• Organising and managing due-diligence.

• SME providing innovation management, product development and commercialisation services to the NHS.
• Business development and licensing negotiations with industry for commercialisation of new technologies.
• Worked alongside Director of Business Development, licensing over 30 new developments.
• Out-licensed the company’s first medical device innovation, plus other developments in cardiology, neurology, emergency medicine, OBGY, diagnostics, and software.
• Helped raise £0.75m funding for a cardiology start-up company.
• Designed and implemented a financial forecasting model to assess the viability of new technologies.

• SME providing innovation management, product development and commercialisation services to the NHS.
• Performed patent and FTO reviews, technical analysis, market and financial evaluation of innovations.
• Developed relationships with university technology transfer, KOLs and key influencers to discover innovative developments and evaluate for investment.
• Worked with hospital executives to increase in-house innovation pipeline.
• Successfully applied for over £0.5m in proof-of-concept funding.
• Commissioned a regional marketing campaign to increase awareness of NHS Innovations London.

• Personalised Medicine Diag. Co.; developing and commercialising a portfolio of pharmacogenetic diagnostics.
• Carried out a market review of pharmacogenetic testing for anti-psychotic drug response including analysis of competitive/complementary technologies, potential investors and M&A targets.
• Supported CEO in preparing presentations and business plans for Series A financing, raising £3m.

• Provides identification services and products: from human genetic disorders to agricultural breed genetics.
• Led a team of five staff to develop and commercialise a new SNP detection technology.
• Successfully diversified business towards agricultural identification services, generating new revenues.
• Initiated and closed the company’s first sales.
• Developed commercial relationships with leading diagnostic companies.

Cambridge, Cambridgeshire, GB

• Worked on site at AstraZeneca as part of a commercial collaboration.
• Developed dielectrophoresis device from ‘proof of principle’ to functional instrument.